<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04219202</url>
  </required_header>
  <id_info>
    <org_study_id>Rad-ONK Retro-Ion</org_study_id>
    <nct_id>NCT04219202</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion</brief_title>
  <acronym>Retro-Ion</acronym>
  <official_title>Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion Prospektive Randomisierte Phase-II-Studie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, open, prospective phase II study. The aim of the study is to
      evaluate the safety and feasibility of a hypofractionated, accelerated radiation approach
      based on the incidence of grade 3-5 NCI Common Terminology Criteria for Adverse Events
      (NCI-CTC-AE ) toxicity and / or termination of the planned therapy for any reason with
      neoadjuvant radiation with active beam guidance of the retroperitoneal Sarcomas using protons
      or carbon ions before a subsequent tumor resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With retroperitoneal sarcomas, the patient benefits from neoadjuvant radiotherapy. Due to the
      special physical properties of particles (protons and C12 carbon ions), in particular the
      steep lateral dose drop, an improved protection of adjacent risk organs is e.g. Intestine,
      kidneys, liver etc. during the process of applying radiotherapy is possible.

      The primary study objective is to demonstrate the safety and conduct of study treatment and
      the incidence of Grade 3-5 NCI-CTC-AE toxicity and / or termination of preferred therapy for
      any reason. Further target parameter is the proportion of applied therapies without the
      occurance of degree 3-5 NCI-CTC-AE(s).

      The patients are randomized 1: 1 into the two arms (carbon ions vs. protons). Patients
      receive 39 Gy in (SD 3.0 Gy) in 6 fractions per week.

      Secondary study objectives are local control (LC), local progression-free survival from the
      start of therapy (LPFS), disease-free survival (DFS), overall survival (OS) and quality of
      life (QoL) determined according to the EORTC-Quality of Life Questionaire (QLQ)- C30
      questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">May 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grad 3-5 NCI-CTC-AE toxicities</measure>
    <time_frame>within 12 month after radiation treatment</time_frame>
    <description>Evidence of the safety and practicability of the study treatment assessed for the incidence of grade 3-5 NCI-CTC-AE toxicity and / or termination of the planned therapy for any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local Tumor control</measure>
    <time_frame>within 12 month after radiation treatment</time_frame>
    <description>Number of patients without new arising Tumors at the treated Tumor site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local Progression free survival</measure>
    <time_frame>within 12 month after radiation treatment</time_frame>
    <description>Number of patients without local Progression at the treated tumor site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>within 12 month after radiation treatment</time_frame>
    <description>Number of Patients without relapse of treated disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>within 12 month after radiation treatment</time_frame>
    <description>Assesment of alive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of live</measure>
    <time_frame>within 12 month after radiation treatment</time_frame>
    <description>Assessed by EORTC QLQ-C30, Minimum value 0; Maximum value 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Sarcoma,Soft Tissue</condition>
  <arm_group>
    <arm_group_label>Proton Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Proton Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbon Ion Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Carbon Ion Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton radiation</intervention_name>
    <description>Therapeutic radiation Treatment with Protons</description>
    <arm_group_label>Proton Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon Ion radiation</intervention_name>
    <description>Therapeutic radiation Treatment with Carbon Ions</description>
    <arm_group_label>Carbon Ion Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed retroperitoneal soft-tissue sarcoma which is resectable or
             marginally resectable

          -  Karnofsky index of â‰¥ 70%

          -  Age from 18 years

          -  Completed patient information and written consent

          -  ability to give consent

        Exclusion Criteria:

          -  Stage IV (distant metastases)

          -  Lymphogenic metastasis

          -  Metal implants at the level of the sarcoma, which influence the treatment planning

          -  Previous radiation therapy in the treatment area

          -  Desmoid tumors, peritoneal sarcomatosis, GIST

          -  Simultaneous participation in another clinical study that could influence the results
             of the respective study

          -  Active medical implants for which there is no license for ion irradiation at the time
             of treatment (e.g. pacemaker, defibrillator)

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juergen Debus, Prof.</last_name>
    <phone>+496221</phone>
    <phone_ext>8201</phone_ext>
    <email>juergen.debus@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katharina Seidensaal, MD</last_name>
    <phone>+496221</phone>
    <phone_ext>8201</phone_ext>
    <email>katharina.seidensaal@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Uhl, PD</last_name>
      <phone>+49-6221-56</phone>
      <phone_ext>8202</phone_ext>
      <email>Matthias.uhl@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Adriane Hommertgen</last_name>
      <phone>+49-6221-56</phone>
      <phone_ext>8202</phone_ext>
      <email>adriane.hommertgen@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Katharina Seidensaal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Princip Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

